Details der Publikation - Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks: a prospective, open-label, randomized controlled trial

Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks: a prospective, open-label, randomized controlled trial : Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks : a prospect

Medienart:	Klinische Studie

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	WHO International Clinical Trials Registry Platform - (2023) vom: 29. Mai Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity in HIV infected patients TDF induced nephrotoxicity, switching, virological response, abacavir, lopinavir/ritonavir;TDF induced nephrotoxicity, switching, virological response, abacavir, lopinavir/ritonavir Phase: Phase 3 Recruitment Status: Completed Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 08-07-2019, Last updated: 2023-06-05

ICTRP ID:	TCTR20190708002

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO004485467

Internformat


LEADER	01000caa a22002652 4500
001	WHO004485467
003	DE-627
005	20230605131117.0
007	cr uuu---uuuuu
008	210507s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)WHO004485467
035			\|a (UBBS_Klinische_Studien_WHO)TCTR20190708002
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks: a prospective, open-label, randomized controlled trial \|b Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks : a prospect
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 08-07-2019, Last updated: 2023-06-05
650		4	\|a Medical Condition: Tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity in HIV infected patients TDF induced nephrotoxicity, switching, virological response, abacavir, lopinavir/ritonavir;TDF induced nephrotoxicity, switching, virological response, abacavir, lopinavir/ritonavir
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Completed
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2023) vom: 29. Mai
773	1	8	\|g year:2023 \|g day:29 \|g month:05
856	4	0	\|u https://www.thaiclinicaltrials.org/show/TCTR20190708002 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
951			\|a AR
952			\|j 2023 \|b 29 \|c 05

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände